Published on
December 1, 2020
- 13:15 GMT
Key Capital Fast-tracking Breakthrough Liver Cancer Immunotherapy
FDA Orphan Drug Designated Immunitor V5 Development to be Accelerated Key Capital Corporation (OTCMKTS:KCPC) NEW YORK, NY, USA, December 1, 2020 /EINPresswire.com/ -- KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that in association with Immunitor …
Distribution channels:
Banking, Finance & Investment Industry, Business & Economy
...
